Additional characterization between pTau distribution (and density) and clinical phenotypes has major implications both for the diagnosis and management of TAND in patients with TSC and for the pathogenesis of 3R/4R tau commonly seen in Alzheimer’s disease. This evidence concerns the gene MAPT and Alzheimer disease.